Evidence map›Paper›PMID 42007743›Full record

ReviewClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Expert Opinion on Implementing Oral Anticoagulation Reversal Protocols in US Hospitals.

Karen Berger, Andrew J Webb, Alyssa D Rabon, Laura E Celmins, Shannon Lovett, Adam Cuker, Alexandra Dixon, Megan A Rech

Abstract readReview
In one paragraph

Review in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karen BergerDepartment of Pharmacy Practice, Nova Southeastern University, Fort Lauderdale, FL, USA.ORCID 0000-0003-3686-3468
Andrew J WebbMassachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-3425-7181
Alyssa D RabonOregon Health & Science University, Portland, OR, USA.ORCID 0009-0001-6335-897X
Laura E CelminsDepartment of Pharmacy, University of Chicago Medical Center, Chicago, IL, USA.ORCID 0000-0003-2249-6150
Shannon LovettDepartment of Emergency Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, IL, USA.ORCID 0000-0001-7952-3477
Adam CukerDepartment of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0002-3595-5697
Alexandra DixonDepartment of Surgery, Legacy Emanuel Medical Center, Portland, OR, USA.
Megan A RechCenter of Innovation for Complex Chronic Healthcare, Hines VA Hospital, Hines, IL, USA.ORCID 0000-0001-6542-518X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral anticoagulants (OACs), including vitamin K antagonists and direct-acting OACs, are commonly used for the prevention and treatment of thrombosis. OAC-treated patients may require urgent anticoagulation reversal in circumstances of life-threatening bleeding or emergent surgery. Despite the availability of Food and Drug Administration-approved OAC reversal agents, published treatment guidelines, and institutional protocols, use of OAC reversal products and dosing vary considerably and off-label use is common. We review key factors influencing current clinical practice and examine barriers to the successful implementation of anticoagulation protocols, including discrepancies in the definition of major bleeding, dosing considerations, variability in laboratory testing practices, inconsistent study endpoints, formulary considerations, and the use of OAC reversal agents in special populations. We provide our expert opinion on best practices for oral anticoagulant reversal and an anticoagulation reversal protocol that could be implemented by healthcare institutions to standardize and optimize clinical practice.

Indexed as

AnticoagulantsAnticoagulation ReversalAdministration, OralHemorrhageHospitalsHumansUnited StatesAnticoagulantsanticoagulationanticoagulation reversalantidoteshemostasisoral anticoagulantsreversal protocols

Identifiers

PMID42007743
PMCPMC13110298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.